Zinger Key Points
- KKR acquires a significant minority stake in Infinx to enhance its growth and support healthcare tech advancements.
- KKR aims to leverage its healthcare expertise and network to boost Infinx's digital transformation and expansion.
KKR & Co. Inc. KKR disclosed the acquisition of significant minority stake in Infinx, a provider of data-driven revenue cycle management solutions for the healthcare sector, with a particular focus on the U.S. market. The financial terms were not disclosed.
With this, KKR expects to leverage its vast experience in the global healthcare and technology sectors to drive Infinx’s growth, boost its network, and aid bolt-on acquisitions.
Akshay Tanna, Partner and Head of India Private Equity, KKR, said, “Digital transformation will play an increasingly important role in helping companies to streamline complex processes and improve productivity. Considering this tailwind, we are pleased to invest in Infinx, given its comprehensive suite of flexible, tech-enabled offerings, strong management team, and proven ability to serve healthcare providers.”
Norwest Venture Partners, an existing shareholder, also participated in the transaction.
Jaideep Tandon, CEO of Infinx, stated, “Infinx has been a leader in the healthcare revenue cycle and an early adopter of automation and AI technologies. With KKR’s support, network and differentiated expertise, we are even better positioned to accelerate our growth, continue our investment in innovative solutions to help improve the financial health of healthcare providers.”
As of first quarter-end, KKR’s cash and investments stood at $14.6 billion.
Investors can gain exposure to the stock via Northern Lights Fund Trust IV FMC Excelsior Focus Equity ETF FMCX and EA Series Trust WHITEWOLF Publicly Listed Private Equity ETF LBO.
Also Read: KKR Goes Surgical: Snags Indian Medical Devices Company Healthium From Apax
Price Action: KKR shares are up 0.13% at $105.01 at the last check Tuesday.
Photo via Shutterstock
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.